Double‐blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: The objective of the study was to evaluate once‐daily extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder (GAD). Methods: An 11‐week (9‐week treatment; 2‐week posttreatment), randomized, double‐blind, placebo‐controlled study (D1448C00015) of flexibly‐dosed quetiapine XR (50–300 mg/day) or placebo conducted at 47 sites (Estonia, Poland, Russia, Ukraine, and USA) between September 2006 and April 2008. Patients (≥66 years) with DSM‐IV diagnosis of GAD, Hamilton Anxiety Rating Scale (HAM‐A) total score of ≥20 with item 1 (anxious mood) and 2 (tension) scores of ≥2, Clinical Global Impressions–Severity of Illness (CGI‐S) score of ≥4, and Montgomery Åsberg Depression Rating Scale (MADRS) total score of ≤16 were eligible for inclusion. Primary endpoint: week 9 change from randomization in HAM‐A total score. Results: Patients were randomized to quetiapine XR (n = 223) or placebo (n = 227). At week 9, quetiapine XR significantly reduced HAM‐A total score versus placebo (least squares mean −14.97 versus −7.21; p < 0.001); symptom improvement with quetiapine XR versus placebo was significant at week 1 (p < 0.001). At week 9, quetiapine XR demonstrated significant benefits over placebo for HAM‐A response and remission rates, HAM‐A psychic and somatic cluster, MADRS total, CGI‐S, Pittsburgh Sleep Quality Index global, pain visual analog scale, and Quality of Life, Enjoyment and Satisfaction Questionnaire short form % maximum total scores and Clinical Global Impressions–Improvement (% patients with a score of 1/2) (all p < 0.001). Adverse events (>5% in either treatment group) included somnolence, dry mouth, dizziness, headache, and nausea. Conclusions: Quetiapine XR (50–300 mg/day) monotherapy is effective in the short term in improving symptoms of anxiety in older patients with GAD, with symptom improvement seen as early as week 1. Tolerability findings were generally consistent with the known profile of quetiapine. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 3×
“During the drug-discontinuation period, treatment discontinuation signs and symptoms (TDSS) were assessed via telephone using an 18-item TDSS scale developed by AstraZeneca as a hybrid of the 17-item discontinuation scale by Michelson et al. (Michelson et al., 2000) and the 43-item Discontinuation Emergent Signs and S…”
MethodBandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citationCurrent Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128
Wetherell, J. L., Le Roux, H., & Gatz, M. (2003) · Psychology and Aging · doi:10.1037/0882-7974.18.3.622 · Cited by 103 · cited 1×
“The positive impact of quetiapine XR treatment on sleep quality in the current study (PSQI global score) benefits this older patient cohort as sleep disturbance is a key feature of late-life GAD (Wetherell et al., 2003).”
Background
Cited by
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“compound has also been evaluated for GAD in geriatric patients [108].”
BackgroundNew Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments
Andreescu, C., & Varon, D. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0595-8 · Cited by 85
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Metadata
- Authors
- Mezhebovsky, I., Mägi, K., She, F., Datto, C., & Eriksson, H.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2012-10-16
- Volume
- 28
- Issue
- 6
- Pages
- 615-625
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1770944666
- Cited by
- 41
- References
- 5
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. https://app.cochat.ai/papers/10.1002/gps.3867
- The paper
- Mezhebovsky, I., Mägi, K., She, F., Datto, C., & Eriksson, H. (2013). Double‐blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.3867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.